Key Financial Highlights

• Market Value & Shares Outstanding: As of June 30, 2025, TELA Bio’s common stock held by non-affiliates had an aggregate market value of approximately \$76.8 million. As of March 16, 2026, there were 44,740,371 shares of common stock outstanding, reflecting potential dilution and capital structure dynamics.
• Listing Status: TELA Bio’s common shares continue to be listed on the Nasdaq Global Market, under the ticker “TELA”. The company notes the importance of maintaining this listing, as delisting could significantly impact share value and capital market access.
• Indebtedness: The report underscores that TELA Bio’s level of indebtedness may limit operational flexibility and adversely affect financial health, making debt covenants and refinancing risks important for investors to monitor.
• Profitability: TELA Bio has incurred significant operating losses since inception, expects to continue operating at a loss, and may not achieve or sustain profitability in the near term. This is a critical point for investors evaluating long-term value and risk.
• Capital Requirements: The company may require substantial additional capital to finance planned operations, and access to such capital is uncertain. This could result in further dilution or financial distress if not managed prudently.

Strategic and Operational Risks

• Sales & Marketing Execution: Success hinges on TELA Bio’s ability to expand, manage, and maintain its direct sales and marketing organization in the U.S. and Europe. Failure could constrain revenue growth.
• Product Commercialization: The commercial success and degree of market acceptance for TELA’s products are uncertain, especially amid the introduction of new products by competitors or perceived negative impacts on demand.
• Competition: TELA operates in a highly competitive market dominated by larger players. The ability to compete and differentiate is crucial for market share and pricing power.
• Coverage & Reimbursement: Achieving and maintaining adequate reimbursement for products is a significant risk, as any changes in policy or pricing could materially affect revenues.
• Regulatory Environment: Extensive government regulation, both in the U.S. and internationally, poses risks related to product approvals, compliance, and potential delays. Regulatory changes (including healthcare reform and inflation-related acts) may also impact operations and profitability.
• Macro-Economic Factors: The report highlights inflation, supply chain disruptions, staffing shortages, and adverse healthcare economic factors as risks that could negatively impact elective surgery volumes and profitability.
• Capital Markets Volatility: Risks include inflationary pressures, interest rate and currency fluctuations, economic downturns, banking instability, trade policy changes, and geopolitical tensions (Russia-Ukraine, Middle East, China-Taiwan). These could affect access to capital, consumer demand, and overall business stability.
• Internal Controls & IP Protection: The company’s ability to develop and maintain corporate infrastructure (including internal controls) and protect intellectual property is vital for long-term competitiveness and operational integrity.
• Cybersecurity: Risks relating to the compromise or corruption of confidential information, personal data, or business relationships could have both financial and reputational impacts.

Shareholder-Sensitive Issues

• Volatility & Listing Risk: TELA Bio acknowledges that its shares have been highly volatile and may continue to be so. Non-compliance with Nasdaq listing standards could lead to delisting, negatively impacting share price and liquidity.
• Executive Compensation & Governance: The report notes documents incorporated by reference regarding executive compensation and corporate governance, which may be of interest to shareholders seeking transparency and alignment.
• Ownership Concentration: Directors, officers, and principal stockholders have significant voting power, potentially influencing decisions not always aligned with other shareholders’ interests.
• Takeover Defenses: Corporate charter provisions and Delaware law may discourage acquisition attempts and limit shareholder influence over management changes.

Forward-Looking Statements and Risk Factors

The company has provided extensive cautionary notes regarding forward-looking statements. These include assumptions about future financial performance, product commercialization, regulatory approvals, competitive dynamics, capital requirements, and macroeconomic impacts. Shareholders should pay particular attention to the “Risk Factors” section for detailed risks that may materially affect future results and share value.

Potential Price-Sensitive Information

• Ongoing Losses & Capital Needs: Continued losses and the possibility of additional capital raises could lead to dilution, debt increases, or financial distress.
• Listing and Compliance Risks: Any issues with Nasdaq listing compliance or material adverse events could trigger sharp share price movements.
• Regulatory or Competitive Developments: Changes in regulation or the introduction of competing products may significantly impact market opportunity and sales.
• Macro-Economic and Geopolitical Volatility: Inflation, interest rates, supply chain issues, and global conflicts could affect operations and investor sentiment.

Conclusion

TELA Bio’s 2025 Annual Report reveals a company facing significant operational, financial, and strategic risks while pursuing growth in the competitive medical device market. Shareholders should closely monitor the company’s ability to raise capital, maintain profitability, navigate regulatory hurdles, and retain its Nasdaq listing. Any material adverse developments in these areas could have a substantial impact on share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with a financial advisor before making investment decisions. The analysis is based on the company’s 2025 Annual Report and may not reflect subsequent developments or announcements.

View TELA Bio, Inc. Historical chart here